Aberdare Ventures
No summary available yet.
Aberdare is healthcare VC royalty that's gone quiet. Paul Klingenstein has an enviable 25-year track record of picking billion-dollar winners like Omada, Nevro, and Castlight, but the fund has basically been sleepwalking since 2021 - their last investment was September 2021. They're the definition of old-school healthcare investors who understand the sector deeply but seem to have missed the AI/digital health wave that younger funds are riding. When they do invest, they write meaningful checks ($8M sweet spot) and actually know what they're doing, but good luck getting their attention right now. The Mohit Kaushal departure in 2014 left them without their digital health champion, and it shows.
- —Best for: Established healthcare companies with proven traction and clear path to $1B+ outcomes
- —Watch out for: Fund appears dormant - haven't made new investments in 3+ years
- —Known for: Deep healthcare expertise and track record of backing unicorns, but risk-averse and slow-moving
Aberdare Ventures is focused exclusively on transformational healthcare companies, with an investment thesis around companies that enable more efficient, less costly, smarter healthcare. The firm focuses on companies that leverage biological, engineering, and information technologies to transform healthcare.
Primarily Series B focused with an average round size of $24.9M, also doing Series A ($9.74M average), Series C ($41.8M), seed ($2.07M), and some Series D deals. Portfolio spans Life Sciences, HealthTech, Enterprise Applications across 36 tech companies, 29 B2B companies, 13 software companies and 7 tech hardware.
Founded Aberdare in 1999 with emphasis on transformational healthcare efficiencies, previously managed healthcare investing at Accel Partners and worked at Warburg Pincus. Harvard undergrad and Stanford MBA, known for backing billion-dollar companies repeatedly.
Former Director of Connected Health at FCC where he established the agency's first dedicated healthcare team and served on the White House Health IT task force, previously at Polaris Venture Partners and Merrill Lynch healthcare investment banking, MD from Imperial College London and Stanford MBA. Left Aberdare in 2014 but brought deep policy and healthcare expertise.
Have a specific question about Aberdare Ventures?
Ask Bernie →